{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:42:28Z","timestamp":1777394548499,"version":"3.51.4"},"reference-count":55,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2017,5,3]]},"DOI":"10.3233\/jad-161116","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T18:24:38Z","timestamp":1490984678000},"page":"23-35","source":"Crossref","is-referenced-by-count":24,"title":["Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"58","author":[{"given":"Stephanie M.","family":"Williams","sequence":"first","affiliation":[{"name":"Chemical Engineering, The School for Engineering of Matter, Transport and Energy, Arizona State University, Tempe, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Schulz","sequence":"additional","affiliation":[{"name":"Chemical Engineering, The School for Engineering of Matter, Transport and Energy, Arizona State University, Tempe, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrone L.","family":"Rosenberry","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Caselli","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Sierks","sequence":"additional","affiliation":[{"name":"Chemical Engineering, The School for Engineering of Matter, Transport and Energy, Arizona State University, Tempe, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-161116_ref1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrn2168","article-title":"Intracellular amyloid-[beta] in Alzheimer\u2019s disease","volume":"8","author":"LaFerla","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-161116_ref2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.nlm.2011.08.003","article-title":"The A\u03b2 oligomer hypothesis for synapse failure and memory loss in Alzheimer\u2019s disease","volume":"96","author":"Ferreira","year":"2011","journal-title":"Neurobiol Learn Mem"},{"key":"10.3233\/JAD-161116_ref3","doi-asserted-by":"crossref","first-page":"e3135","DOI":"10.1371\/journal.pone.0003135","article-title":"Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"3","author":"Tsigelny","year":"2008","journal-title":"PLoS One"},{"key":"10.3233\/JAD-161116_ref4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bcp.2013.12.023","article-title":"Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins","volume":"88","author":"Guerrero-Mu\u00f1oz","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.3233\/JAD-161116_ref5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","article-title":"Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers","volume":"88","author":"Reitz","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.3233\/JAD-161116_ref6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.arr.2013.03.002","article-title":"The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer\u2019s disease","volume":"12","author":"Crimins","year":"2013","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-161116_ref7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","article-title":"Tau-aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"88","author":"Wischik","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"Part A","key":"10.3233\/JAD-161116_ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.018","article-title":"A role for tau at the synapse in Alzheimer\u2019s disease pathogenesis","volume":"76","author":"Pooler","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-161116_ref9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2013\/260787","article-title":"Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations","volume":"2013","author":"Tian","year":"2013","journal-title":"Int J Cell Biol"},{"key":"10.3233\/JAD-161116_ref10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2012.06.017","article-title":"Plasma amyloid-\u03b2 oligomers level is a biomarker for Alzheimer\u2019s disease diagnosis","volume":"423","author":"Zhou","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3233\/JAD-161116_ref11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.celrep.2014.02.031","article-title":"Detection of misfolded A\u03b2 oligomers for sensitive biochemical diagnosis of Alzheimer\u2019s disease","volume":"7","author":"Salvadores","year":"2014","journal-title":"Cell Reports"},{"key":"10.3233\/JAD-161116_ref12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0166-2236(00)01749-5","article-title":"Targeting small A\u03b2 oligomers: The solution to an Alzheimer\u2019s disease conundrum?","volume":"24","author":"Klein","year":"2001","journal-title":"Trends Neurosci"},{"key":"10.3233\/JAD-161116_ref13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.nbd.2013.03.004","article-title":"Deleterious effects of soluble amyloid-\u03b2 oligomers on multiple steps of synaptic vesicle trafficking","volume":"55","author":"Park","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-161116_ref14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jalz.2012.11.005","article-title":"New ELISAs with high specificity for soluble oligomers of amyloid \u03b2-protein detect natural A\u03b2 oligomers in human brain but not CSF","volume":"9","author":"Yang","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161116_ref15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bcp.2013.12.020","article-title":"Immunotherapy for Alzheimer\u2019s disease","volume":"88","author":"Wisniewski","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.3233\/JAD-161116_ref16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jneumeth.2008.09.002","article-title":"Characterisation of two antibodies to oligomeric A\u03b2 and their use in ELISAs on human brain tissue homogenates","volume":"176","author":"van Helmond","year":"2009","journal-title":"J Neurosci Methods"},{"key":"10.3233\/JAD-161116_ref17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jmb.2008.09.068","article-title":"Anti-oligomeric A\u03b2 single-chain variable domain antibody blocks A\u03b2-induced toxicity against human neuroblastoma cells","volume":"384","author":"Zameer","year":"2008","journal-title":"J Mol Biol"},{"key":"10.3233\/JAD-161116_ref18","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.neurobiolaging.2010.09.020","article-title":"Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form","volume":"33","author":"Kasturirangan","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-161116_ref19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/btpr.1698","article-title":"Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples","volume":"29","author":"Kasturirangan","year":"2013","journal-title":"Biotechnol Prog"},{"key":"10.3233\/JAD-161116_ref20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejn.13056","article-title":"Oligomeric \u03b1-synuclein and \u03b2-amyloid variants as potential biomarkers for Parkinson\u2019s and Alzheimer\u2019s diseases","volume":"43","author":"Williams","year":"2016","journal-title":"Eur J Neurosci"},{"key":"10.3233\/JAD-161116_ref21","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.neurobiolaging.2014.12.002","article-title":"Isolation and characterization of antibody fragments selective for toxic oligomeric tau","volume":"36","author":"Tian","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-161116_ref22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00401-014-1269-z","article-title":"TDP-43 is a key player in the clinical features associated with Alzheimer\u2019s disease","volume":"127","author":"Josephs","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-161116_ref23","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1111\/j.1742-4658.2011.08256.x","article-title":"TDP-43: The relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration","volume":"278","author":"Baloh","year":"2011","journal-title":"FEBS J"},{"key":"10.3233\/JAD-161116_ref24","first-page":"147","article-title":"TDP-43 in aging and Alzheimer\u2019s disease - a review","volume":"4","author":"Wilson","year":"2011","journal-title":"Int J Clin Exp Pathol"},{"key":"10.3233\/JAD-161116_ref25","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1038\/ncomms5824","article-title":"Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients","volume":"5","author":"Fang","year":"2014","journal-title":"Nat Commun"},{"issue":"96","key":"10.3233\/JAD-161116_ref26","first-page":"52584","article-title":"Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis","author":"Williams","year":"2015","journal-title":"J Vis Exp"},{"issue":"Suppl 3","key":"10.3233\/JAD-161116_ref27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3233\/JAD-2011-0043","article-title":"Disease tracking markers for Alzheimer\u2019s disease at the prodromal (MCI) stage","volume":"26","author":"Drago","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-161116_ref28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10561-008-9067-2","article-title":"The sun health research institute brain donation program: Description and experience, 1987\u20132007","volume":"9","author":"Beach","year":"2008","journal-title":"Cell Tissue Banking"},{"key":"10.3233\/JAD-161116_ref29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/neup.12189","article-title":"Arizona study of aging and neurodegenerative disorders and brain and body donation program","volume":"35","author":"Beach","year":"2015","journal-title":"Neuropathology"},{"key":"10.3233\/JAD-161116_ref30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/btpr.1987","article-title":"A Sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samples","volume":"31","author":"Williams","year":"2015","journal-title":"Biotechnol Prog"},{"key":"10.3233\/JAD-161116_ref31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12868-017-0334-7","article-title":"TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis","volume":"18","author":"Williams","year":"2017","journal-title":"BMC Neurosci"},{"key":"10.3233\/JAD-161116_ref32","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1074\/jbc.M507892200","article-title":"Temporal profile of amyloid-\u03b2 (A\u03b2) oligomerization in an model of Alzheimer disease: A link between A\u03b2 and tau pathology","volume":"281","author":"Oddo","year":"2006","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-161116_ref33","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1021\/cn400129p","article-title":"Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer\u2019s disease","volume":"4","author":"Chiu","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/JAD-161116_ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-5-51","article-title":"Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to A\u03b2 oligomers accumulation","volume":"5","author":"Caccamo","year":"2010","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-161116_ref35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmb.2010.10.054","article-title":"Inhibiting \u03b2-secretase activity in Alzheimer\u2019s disease cell models with single-chain antibodies specifically targeting APP","volume":"405","author":"Boddapati","year":"2011","journal-title":"J Mol Biol"},{"key":"10.3233\/JAD-161116_ref36","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3233\/JAD-2011-111196","article-title":"Bispecific tandem single chain antibody simultaneously inhibits \u03b2-secretase and promotes \u03b1-secretase processing of A\u03b2PP","volume":"28","author":"Boddapati","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-161116_ref37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tibtech.2010.09.007","article-title":"Identifying and validating biomarkers for Alzheimer\u2019s disease","volume":"29","author":"Humpel","year":"2011","journal-title":"Trends Biotechnol"},{"key":"10.3233\/JAD-161116_ref38","first-page":"606802","article-title":"CSF biomarkers for Alzheimer\u2019s disease diagnosis","volume":"2010","author":"Anoop","year":"2010","journal-title":"Int J Alzheimers Dis"},{"key":"10.3233\/JAD-161116_ref39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(15)00150-7","article-title":"Biomarkers for Alzheimer\u2019s disease: A controversial topic","volume":"14","author":"Frisoni","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-161116_ref40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S1474-4422(15)00135-0","article-title":"Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer\u2019s disease: A prospective cohort study","volume":"14","author":"Yau","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-161116_ref41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","article-title":"Biomarkers for Alzheimer\u2019s disease: Academic, industry and regulatory perspectives","volume":"9","author":"Hampel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.3233\/JAD-161116_ref42","first-page":"70","article-title":"Body fluid biomarkers in Alzheimer\u2019s disease","volume":"3","author":"Lu","year":"2015","journal-title":"Ann Transl Me"},{"key":"10.3233\/JAD-161116_ref43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1756285612455367","article-title":"Neurochemical biomarkers in Alzheimer\u2019s disease and related disorders","volume":"5","author":"Bibl","year":"2012","journal-title":"Ther Adv Neurol Disord"},{"key":"10.3233\/JAD-161116_ref44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-161116_ref45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrn3887","article-title":"Spreading of pathology in neurodegenerative diseases: A focus on human studies","volume":"16","author":"Brettschneider","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-161116_ref46","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fneur.2015.00236","article-title":"Blood based proteomic biomarkers of Alzheimer\u2019s disease pathology","volume":"6","author":"Baird","year":"2015","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-161116_ref47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jalz.2012.12.006","article-title":"Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer\u2019s disease","volume":"10","author":"Rembach","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161116_ref48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt162","article-title":"Plasma amyloid beta measurements - a desired but elusive Alzheimer\u2019s disease biomarker","volume":"5","author":"Toledo","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-161116_ref49","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jalz.2012.01.001","article-title":"Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer\u2019s Disease Neuroimaging Initiative study patients","volume":"8","author":"Figurski","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-161116_ref50","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2183\/pjab.90.353","article-title":"Novel plasma biomarker surrogating cerebral amyloid deposition","volume":"90","author":"Kaneko","year":"2014","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.3233\/JAD-161116_ref51","doi-asserted-by":"crossref","first-page":"e68996","DOI":"10.1371\/journal.pone.0068996","article-title":"Increased levels of antigen-bound \u03b2-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer\u2019s disease patients","volume":"8","author":"Maftei","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JAD-161116_ref52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic A[beta] oligomer and Alzheimer\u2019s disease: An emperor in need of clothes","volume":"15","author":"Benilova","year":"2012","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-161116_ref53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer\u2019s amyloid [beta]-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.3233\/JAD-161116_ref54","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-161116_ref55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1042\/BST20120134","article-title":"Tau oligomers and tau toxicity in neurodegenerative disease","volume":"40","author":"Ward","year":"2012","journal-title":"Biochem Soc Trans"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-161116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:03:38Z","timestamp":1777370618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-161116"}},"subtitle":[],"editor":[{"given":"Gary","family":"Arendash","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,3]]},"references-count":55,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-161116","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,3]]}}}